Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
NATRIUMRISEDRONAAT 1-WATER SAMENSTELLING overeenkomend met ; NATRIUMRISEDRONAAT 0-WATER ; SAMENSTELLING overeenkomend met RISEDRONINEZUUR
Sandoz B.V. Veluwezoom 22 1327 AH ALMERE
M05BA07
NATRIUMRISEDRONAAT 1-WATER COMPOSITION corresponding to ; NATRIUMRISEDRONAAT 0-WATER ; COMPOSITION corresponding to RISEDRONINEZUUR
Filmomhulde tablet
IJZEROXIDE ROOD (E 172) ; LACTOSE 1-WATER ; MACROGOL 3350 ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL ; MAÏSZETMEEL, GEPREGELATINEERD ; NATRIUMSTEARYLFUMARAAT ; POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203) ; SILICIUMDIOXIDE (E 551) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171),
Oraal gebruik
Risedronic Acid
Hulpstoffen: IJZEROXIDE ROOD (E 172); LACTOSE 1-WATER; MACROGOL 3350; MAGNESIUMSTEARAAT (E 470b); MAÏSZETMEEL; MAÏSZETMEEL, GEPREGELATINEERD; NATRIUMSTEARYLFUMARAAT; POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203); SILICIUMDIOXIDE (E 551); TALK (E 553 B); TITAANDIOXIDE (E 171);
2011-08-23
Sandoz B.V. Page 1/7 Natriumrisedronaat Sandoz 75 mg, filmomhulde tabletten RVG 107797 V12 1.3.1.3 Bijsluiter Mei 2020 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT NATRIUMRISEDRONAAT SANDOZ ® 75 MG, FILMOMHULDE TABLETTEN risedronate sodium READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What [Nationally completed name] is and what it is used for 2. What you need to know before you take [Nationally completed name] 3. How to take [Nationally completed name] 4. Possible side effects 5. How to store [Nationally completed name] 6. Contents of the pack and other information 1. WHAT [NATIONALLY COMPLETED NAME] IS AND WHAT IT IS USED FOR WHAT [NATIONALLY COMPLETED NAME] IS [Nationally completed name] belongs to a group of non-hormonal medicines called bisphosphonates that are used to treat bone diseases. It works directly on your bones to make them stronger and therefore less likely to break. Bone is a living tissue. Old bone is constantly removed from your skeleton and replaced with new bone. Postmenopausal osteoporosis is a condition occurring in women after the menopause where the bones become weaker, more fragile and more likely to break after a fall or strain. The spine, hip and wrist are the most likely bones to break, although this can happen to any bone in your body. Osteoporosis-related fractures can also cause back pain, height loss and a curved back. Many patients with osteoporosis have no symptoms and you may not even have known that you had it. WHAT [NATIONALLY COMPLETED NAME] IS USED FOR The t Lees het volledige document
Sandoz B.V. Page 1/10 Natriumrisedronaat Sandoz 75 mg, filmomhulde tabletten RVG 107797 V8 1.3.1.1 Samenvatting van de Productkenmerken Mei 2020 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Natriumrisedronaat Sandoz 75 mg, filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of risedronate sodium, equivalent to 69.6 mg risedronic acid. _ _ Excipient with known effect Each film-coated tablet contains 299.8 mg of lactose monohydrate (equivalent to 284.8 mg lactose). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Pink, round, biconvex, marked with “R 75” on one side and plain on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of osteoporosis in postmenopausal women at increased risk of fractures (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose in adults is one 75 mg tablet orally on two consecutive days a month. The first tablet should be taken on the same day each month, followed by the second tablet the next day. The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of [Nationally completed name] 75mg film-coated tablets on an individual patient basis, particularly after 5 or more years of use. The absorption of risedronate sodium is affected by food and polyvalent cations (see section 4.5), thus to ensure adequate absorption patients should take the tablet before breakfast: at least 30 minutes before the first food, other medicinal product or drink (other than plain water) of the day. Plain water is the only drink that should be taken with risedronate 75 mg tablets. Please note that some mineral water may have a higher concentration of calcium and therefore should not be used (see section 5.2). Patients who miss a dose should be instructed to take one tablet the morning after th Lees het volledige document